TSRO Can AZN Keep Up As CLVS, TSRO Unveil BB Drugs?
Jun 19, 2017 13:52:48 GMT
via Tapatalk
icemandios likes this
Post by tomsylver on Jun 19, 2017 13:52:48 GMT
TECHNOLOGY
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
ALLISON GATLIN6/16/2017
Clovis Oncology (CLVS) and Tesaro (TSRO) could each deliver blockbuster ovarian cancer drugs and grab takeover interest, an analyst said Friday ahead of a key trial for Clovis, expected later this month.
The duo rivals bigger AstraZeneca (AZN), whose $87.3 billion market cap is more than eight times that of Clovis and Tesaro combined. Clovis and Tesaro joined AstraZeneca on the PARP-inhibitor market within the last year.
PARP inhibitors work by blocking a family of enzymes that cancer cells use to proliferate. Pfizer (PFE) and AbbVie (ABBV) are also working on PARP inhibitors. Credit Suisse analyst Alethia Young sees the class of drugs also having an impact in prostate, breast and lung cancers.
"We think that the PARP (inhibitor) market is big enough ($8 billion to $10 billion) that Clovis can have a blockbuster product as well," she wrote. "We strongly believe that both companies are likely attractive targets for large global biopharma companies."
Later this month, Clovis is expected to unveil the results of its Phase 3 trial, dubbed Ariel-3, for its drug Rubraca. Tesaro previously set a high bar with a trial of its drug Zejula which had a benefit in all patients regardless of specific genetics.
"On a top-line basis, we think Ariel-3 will work across the groups, but the focus will be on potential commercial differences like use of biomarker and safety," she wrote in a note to clients.
Young expects Tesaro stock to be volatile following Clovis' trial, but notes that it will lift an overhang on shares. She has outperform ratings on both Tesaro and Clovis stocks. She rates Tesaro stock with a 198 price target and Clovis with an 88 price target, up from 74.
On the stock market today, Clovis stock rose 0.45% to 59.97. Tesaro stock gained 0.1% to 144.31. AstraZeneca, Pfizer and AbbVie stocks were up 1.4%, 0.5% and 0.6%, respectively.
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
ALLISON GATLIN6/16/2017
Clovis Oncology (CLVS) and Tesaro (TSRO) could each deliver blockbuster ovarian cancer drugs and grab takeover interest, an analyst said Friday ahead of a key trial for Clovis, expected later this month.
The duo rivals bigger AstraZeneca (AZN), whose $87.3 billion market cap is more than eight times that of Clovis and Tesaro combined. Clovis and Tesaro joined AstraZeneca on the PARP-inhibitor market within the last year.
PARP inhibitors work by blocking a family of enzymes that cancer cells use to proliferate. Pfizer (PFE) and AbbVie (ABBV) are also working on PARP inhibitors. Credit Suisse analyst Alethia Young sees the class of drugs also having an impact in prostate, breast and lung cancers.
"We think that the PARP (inhibitor) market is big enough ($8 billion to $10 billion) that Clovis can have a blockbuster product as well," she wrote. "We strongly believe that both companies are likely attractive targets for large global biopharma companies."
Later this month, Clovis is expected to unveil the results of its Phase 3 trial, dubbed Ariel-3, for its drug Rubraca. Tesaro previously set a high bar with a trial of its drug Zejula which had a benefit in all patients regardless of specific genetics.
"On a top-line basis, we think Ariel-3 will work across the groups, but the focus will be on potential commercial differences like use of biomarker and safety," she wrote in a note to clients.
Young expects Tesaro stock to be volatile following Clovis' trial, but notes that it will lift an overhang on shares. She has outperform ratings on both Tesaro and Clovis stocks. She rates Tesaro stock with a 198 price target and Clovis with an 88 price target, up from 74.
On the stock market today, Clovis stock rose 0.45% to 59.97. Tesaro stock gained 0.1% to 144.31. AstraZeneca, Pfizer and AbbVie stocks were up 1.4%, 0.5% and 0.6%, respectively.